title: Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study.
abstract: OBJECTIVE
  Switching patients with Alzheimer's disease from one cholinesterase inhibitor to another represents a viable option for patients not responding to current therapy. The objective of this large U.S.-based study was to evaluate the safety and efficacy of a treatment switch to rivastigmine in patients not responding adequately to or declining on treatment with donepezil.
  
  
  METHODS
  In this 26-week, prospective, open-label, single-arm, multicenter study conducted from April 24, 2003, to June 25, 2004, patients with mild-to-moderate Alzheimer's disease (DSM-IV-TR criteria) who were not responding to donepezil were treated with rivastigmine 3-12 mg/day. Safety and tolerability were measured by the occurrence of adverse events and patient disposition. Treatment effects on global functioning were assessed using the Clinical Global Impression of Change (CGIC) scale.
  
  
  RESULTS
  Two hundred seventy patients with a mean age of 78.5 (SD = 7.56) years and a mean duration of dementia of 3.5 (SD = 2.06) years were included in the study. Sixty-nine percent of patients completed the study with 17.8% discontinuing due to adverse events. Eighty-three percent of patients reported at least 1 adverse event, with the most frequently occurring adverse events affecting the gastrointestinal system (54%). The majority of patients were reported to have either improvement or no decline on the CGIC. A limitation of the study is that the interpretation of the results is based on an overall completion rate of 69%.
  
  
  CONCLUSIONS
  Immediately switching patients from donepezil to rivastigmine without a washout period was safe and well tolerated in the current study. Additionally, these results suggest that patients not responding adequately to or declining while taking donepezil may improve or stabilize after switching to rivastigmine.
authors.affiliation: Southeastern Geriatric Healthcare Group, Snellville, Ga, USA.
authors.forename: Gary S
authors.initials: GS
authors.lastname: Figiel
authors.forename: Carl H
authors.initials: CH
authors.lastname: Sadowsky
authors.forename: John
authors.initials: J
authors.lastname: Strigas
authors.forename: Barbara
authors.initials: B
authors.lastname: Koumaras
authors.forename: Xiangyi
authors.initials: X
authors.lastname: Meng
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Gunay
references.citation: Am J Geriatr Psychiatry. 2003 Mar-Apr;11(2):131-45
references.pmid: 12611743
references.citation: J Am Osteopath Assoc. 2005 Mar;105(3):145-58
references.pmid: 15863734
references.citation: Neurology. 2001 May 8;56(9):1154-66
references.pmid: 11342679
references.citation: Curr Med Res Opin. 2002;18(3):129-38
references.pmid: 12094822
references.citation: Int J Clin Pract. 2006 Jan;60(1):110-8
references.pmid: 16409439
references.citation: Arch Neurol. 2001 Mar;58(3):427-33
references.pmid: 11255446
references.citation: Prim Care Companion J Clin Psychiatry. 2005;7(2):43-48
references.pmid: 15841194
references.citation: Curr Med Res Opin. 2003;19(8):707-14
references.pmid: 14687441
references.citation: Neurology. 1984 Jul;34(7):939-44
references.pmid: 6610841
references.citation: Arch Intern Med. 1998 May 11;158(9):1021-31
references.pmid: 9588436
references.citation: Gerontologist. 1991 Feb;31(1):76-83
references.pmid: 2007478
references.citation: Alzheimer Dis Assoc Disord. 2005 Oct-Dec;19(4):186-94
references.pmid: 16327345
references.citation: Neurology. 1998 Jan;50(1):136-45
references.pmid: 9443470
references.citation: J Psychiatr Res. 1975 Nov;12(3):189-98
references.pmid: 1202204
references.citation: Int J Geriatr Psychiatry. 2002 Mar;17(3):288-9
references.pmid: 11921158
references.citation: Arch Neurol. 2000 Jan;57(1):94-9
references.pmid: 10634454
references.citation: Neurology. 1994 Dec;44(12):2308-14
references.pmid: 7991117